AR129420A1 - Nuevos derivados para tratar trastornos mediados por trpm3 - Google Patents

Nuevos derivados para tratar trastornos mediados por trpm3

Info

Publication number
AR129420A1
AR129420A1 ARP230101303A ARP230101303A AR129420A1 AR 129420 A1 AR129420 A1 AR 129420A1 AR P230101303 A ARP230101303 A AR P230101303A AR P230101303 A ARP230101303 A AR P230101303A AR 129420 A1 AR129420 A1 AR 129420A1
Authority
AR
Argentina
Prior art keywords
trpm3
mediated disorders
treat
new derivatives
prevention
Prior art date
Application number
ARP230101303A
Other languages
English (en)
Inventor
Arnaud Marchand
Jean Vanherck
- Reich Melanie Christophe
Sebastian Krger
Thomas Vriens Joris Voets
Original Assignee
Univ Leuven Kath
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Biohaven Therapeutics Ltd filed Critical Univ Leuven Kath
Publication of AR129420A1 publication Critical patent/AR129420A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se relaciona con compuestos que son útiles para la prevención o tratamiento de trastornos mediados por TRPM3, más en particular trastornos seleccionados de dolor, epilepsia e hipersensibilidad inflamatoria. La invención también se relaciona con un método para la prevención o tratamiento de dichos trastornos mediados por TRPM3. Un compuesto de la fórmula (1), una forma estereomérica, una sal, solvato y/o polimorfo fisiológicamente aceptables. Una composición farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 11.
ARP230101303A 2022-05-25 2023-05-24 Nuevos derivados para tratar trastornos mediados por trpm3 AR129420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22175494 2022-05-25

Publications (1)

Publication Number Publication Date
AR129420A1 true AR129420A1 (es) 2024-08-21

Family

ID=81850222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101303A AR129420A1 (es) 2022-05-25 2023-05-24 Nuevos derivados para tratar trastornos mediados por trpm3

Country Status (3)

Country Link
AR (1) AR129420A1 (es)
TW (1) TW202411211A (es)
WO (1) WO2023227695A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
KR20050065661A (ko) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
US8445497B2 (en) * 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9303020B2 (en) * 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2014113620A2 (en) * 2013-01-18 2014-07-24 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
US9738653B2 (en) * 2013-03-14 2017-08-22 Bristol-Myers Squibb Company Fused furans for the treatment of hepatitis C
EP3080106B1 (en) * 2013-12-13 2018-01-31 Bristol-Myers Squibb Company A novel compound for the treatment of hepatitis c
US20230391739A1 (en) * 2020-11-24 2023-12-07 Katholieke Universiteit Leuven Aryl derivatives for treating trpm3 mediated disorders
WO2022112352A1 (en) * 2020-11-24 2022-06-02 Katholieke Universiteit Leuven Heterocycle derivatives for treating trpm3 mediated disorders

Also Published As

Publication number Publication date
TW202411211A (zh) 2024-03-16
WO2023227695A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
BRPI0607926A2 (pt) compostos espiro-oxindol e seus usos como agentes terapêuticos
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
BRPI0410081A (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
ECSP056118A (es) Derivados de alcanos azaespiro como inhibidores de las metaloproteasas
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112022017099A2 (pt) Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc
EP4226932A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF PERIODONTAL DISEASE OR LUXATED TEETH
IL299762A (en) Useful preparations for the treatment of Charcot-Marietot disease
UY39799A (es) Compuestos de pirrolil–sulfonamida
UY39516A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
AR129420A1 (es) Nuevos derivados para tratar trastornos mediados por trpm3
AR129422A1 (es) Nuevos derivados para tratar trastornos mediados por trpm3
AR129421A1 (es) Nuevos derivados para tratar trastornos mediados por trpm3
AR129419A1 (es) Nuevos derivados para tratar trastornos mediados por trpm3
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
EP4149519A4 (en) COMPOSITIONS FOR THE TREATMENT OF POMPE DISEASE